Stéphane Bancel, Moderna CEO (Christopher Goodney/Bloomberg via Getty Images)
Moderna looks past post-Covid 'low point' at a future based on combination vaccines, cancer indications
The Covid boom is over at Moderna.
On Thursday, the biotech said it was bracing for sales to “hit a low point” in 2024 as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
